Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo Clears Listing for Yorvipath and More Drugs; Zero Premium Rule Weighs Yet Again
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the official NHI listing date set for October 22. This time, Teijin Pharma’s hypoparathyroidism therapy Yorvipath (palopegteriparatide) fell prey to the…
To read the full story
Related Article
- Aculys Rolls Out Spydia Nasal Spray in Japan
December 25, 2025
- Izervay, Vorzzz, Dormicum Syrup Now Available in Japan
November 28, 2025
- Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
- Santen Rolls Out Glaucoma Drug Setaneo in Japan
October 24, 2025
- GSK’s Blenrep, BMS’s Inrebic Absent from October Listing Roster
October 17, 2025
- Japan Approves 3 New Drugs, Expands Label for Enhertu, Silgard 9 and More
August 26, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
REGULATORY
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
- Three Sent to Prosecutors over Alleged Illegal Mounjaro Sales
June 3, 2026
- LDP Group Eyes Proposal to Address Challenges in Radiopharmaceutical Use
June 3, 2026
- Japan OKs Dosage Change for Colchicine after Fatal High-Dose Cases
June 3, 2026
- Japan Measles Cases Top 500 This Year: JIHS
June 3, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…